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Background: From previous reviews, there still have been controversies over the effect of metformin (MET) on
reproductive function in PCOS patients. The reasons for the inconsistent findings especially lie in the transparency
and accuracy of randomized controlled trials (RCTs) reports. However, we could find no data about the quality of
RCTs reporting in MET for PCOS. Thus, a retrospective survey related to the quality of reporting in MET for PCOS
was conducted.
Methods: A retrospective survey was conducted by two investigators. Two investigators assessed the quality of
overall reporting and key methodological factors reporting using items from the CONSORT 2010 statement.
Results: A total of 39 RCTs were included in full text. The median overall quality score was 9, with a minimum of 2
and a maximum of 13. Good or general reporting existed in 11 items with positive rate of more than or equal to
50%. The median score of key methodological items was 4 with a minimum of 0 and a maximum of 5.
Randomization, allocation concealment, blinding, baseline characteristics and intention-to-treat (ITT) analysis were
reported in 26 (67%), 19 (49%), 20 (51%), 38 (97%) and 17 (44%) of the 39 RCTs, respectively. After adjustment, the
mean overall score increased by about 1.71 for manuscripts with funding source (95% CI, 0.18 to 3.24), while it
increased by about 3.51 for manuscripts published in one year increment (95% CI, 1.82 to 5.19). There was a
relatively close, significant correlation (r = 0.589, P < 0.001) between the score of overall reporting quality and year of
publication.
Conclusion: Although the overall reporting quality of RCTs in MET for PCOS has improved over time, reporting of
key methodological items remains poor. Reporting of RCTs on MET for PCOS should keep up with the standards of
the CONSORT statement.
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Polycystic ovary syndrome (PCOS) is characterized by
chronic anovulation (failure or absence of ovulation) and
hyperandrogenism (excessive production of male hormones
in women) with clinical manifestations of irregular men-
strual cycles, infertility, hirsutism, and acne [1], which is a
common condition affecting women of reproductive age
in 5 to 10% [2].* Correspondence: baoyingchen2013@126.com
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reproduction in any medium, provided the orAdministration of clomiphene citrate (CC) is the
standard treatment for PCOS patients with anovulatory
infertility. However, clomiphene resistance (failure to ovu-
late after taking clomiphene) is common, occurring in ap-
proximately 15 to 40% of women with PCOS [3]. In 2008,
it was reported that insulin resistance was a significant
contributor to the pathogenesis of PCOS [4]. Because of
the insulin resistance in the pathogenesis of PCOS, met-
formin (MET), a biguanide and insulin-sensitizing drug
used in the treatment of type 2 diabetes mellitus, was
applied to the treatment of infertile women with PCOS
before or during the ovulation induction [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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have evaluated the efficacy of metformin in the treatment
of anovulation because of PCOS. Most of these reviews
concluded that metformin monotherapy represented a
safe and valid therapeutic option for improving ovulation
in PCOS patients. One review [13] concluded that com-
bination of MET and CC could gain advantage over a
single administration in the ovulation induction and
pregnancy rate, but another review [12] concluded this
combination was no better than monotherapy (MET
alone or CC alone). Moreover, there still have been con-
troversies over the effect of MET on reproductive func-
tion in PCOS patients [14-17].
Randomized controlled trials (RCTs) are widely ac-
cepted as the ‘gold standard’ for accumulating strong
evidence for any health care intervention. Moreover,
quality of reporting is essential for guiding journal
peer-review decisions and experts’ recommendations,
conducting unbiased meta-analysis and influencing
our interpretation of evidence [18]. The reasons for
the inconsistent findings of above reviews lie in the
bias of literature search and screening and especially
the transparency and accuracy of RCT reports. The
Consolidated Standards of Reporting Trials (CONSORT)
statement is an international consensus expert guideline
developed in 1996 and last updated in 2010, aimed at
improving the reporting quality of published RCTs [19].
The CONSORT is widely accepted in the field of clinical
trials and is supported by a growing number of health
care journals and editorial groups.
However, we could find no data about the quality of
RCTs reporting in MET for PCOS. Thus, a retrospective
survey related to the quality of reporting in MET for
PCOS was conducted. The aim of this study was to as-
sess the overall quality of published articles of random-
ized trials in MET for PCOS with a special focus on the
key methodological items that safeguard against biases,
namely appropriate randomization, allocation conceal-
ment, blinding, baseline characteristics and analysis ac-
cording to intention-to-treat (ITT) principle. Secondarily,




A systematic and comprehensive literature search was
conducted with the aim of identifying published prospect-
ive RCTs of MET for PCOS. No resources were available
to search literature published in languages other than
English.
The following databases were searched from their in-
ception through February 2013: MEDLINE, EMBASE,
the Cochrane Central Register of Controlled Trials
(CENTRAL), and CINAHL.Keywords were approved by all the authors and included
‘PCOS’, ‘polycystic ovary syndrome’, ‘metformin’, ‘MET’,
‘clomiphene citrate’, ‘CC’, ‘randomized trials’, ‘RCT’. Eli-
gible articles were identified by successive screening of
titles and abstracts. Then the references section of each
printed article was screened to identify any additional
eligible articles.
Inclusion and exclusion criteria
Types of studies: only RCTs of MET for PCOS were
identified and selected for the analysis. Specifically, retro-
spective, non-randomized, cross-over RCTs, case-control,
and quasi-randomized trials, abstracts in conference and
case reports/series were excluded.
The criteria in terms of PCOS diagnosis had to be con-
sistent with those as follows: oligo- or anovulation, clinical
or biochemical signs of hyperandrogenism and polycystic
ovaries visible with ultrasound. The RCTs on the effects
on MET in patients who received gonadotrophins for IVF
and not-IVF cycles were also included. Several different
types of interventions were analyzed: MET versus placebo,
MET versus CC, MET plus CC versus CC, MET plus CC
versus MET. We also included trials in which MET com-
bined with other interventions as the treatment group (for
example, MET plus lifestyle versus placebo plus lifestyle,
MET plus rFSH versus rFSH). The primary comparison
was always between MET and the other treatment. Out-
comes included live birth rate, rates of ovulation, preg-
nancy, abortion and discontinuation for adverse events.
Assessment of reporting quality
Rating of overall reporting quality
An overall quality score with 13 items from the CONSORT
2010 statement was used (Table 1). Each item was
scored 1 if it was reported and 0 if it was not clearly, or
definitely not stated. These were among the items se-
lected by previous evaluation studies of the CONSORT
statement [20-23].
Rating of key methodological items
Five key methodological categories of randomization,
allocation concealment, blinding, baseline characteristics
and ITT analysis have been assessed separately because
they relate to potential sources of bias [24-26]. We then
developed eight ‘yes’/‘no’ items (Table 2), wording so
that emphasis was placed on quality of reporting rather
than adequacy of trial design. Each item was scored 1 if
the method was appropriate and 0 if inappropriate or if
the reporting was unclear.
Data extraction
One of the investigators (Minyan Li) looked at the title,
abstract and methodology of all the published papers
to identify them as RCTs. General information (year of
Table 1 Overall quality of reporting rating using items from the CONSORT statement (n = 39)
Item Criteria Description Number. of
positive trials






Study identified as a randomized controlled in the
title or abstract
36 92 84 to 100 1 1
2 Background Adequate description of the scientific background and
explanation of rationale
38 97 92 to 100 0.62 0.35 to 0.95
3 Trial design Description of trial design (such as parallel, factorial)
including allocation ratio
34 87 76 to 98 0.74 0.52 to 0.98
4 Participants Description of the eligibility criteria for participants 36 92 84 to 100 0.92 0.83 to 1.00
5 Interventions Details of the interventions intended for each group 35 90 80 to 100 0.63 0.42 to 0.98
6 Outcomes Definition of primary (and secondary when appropriate)
outcome measures
23 59 43 to 75 0.81 0.65 to 0.99
7 Sample size Description of sample size calculation 19 49 32 to 65 0.78 0.54 to 0.97
12 Statistical
methods
Description of the statistical methods used to compare groups
for primary outcomes, subgroup analyses, or adjusted analyses
29 74 60 to 89 0.68 0.43 to 0.96
13 Flow chart Details on the flow of participants through each stage of the trials
(number of patients randomly assigned, receiving intended
treatment, completing the protocol and analyzed)
21 54 37 to 70 0.93 0.85 to 1.00
14 Recruitment Dates defining the periods of recruitment and follow-up 20 51 35 to 68 0.54 0.36 to 0.92
17 Outcomes and
estimation
For each primary and secondary outcome, a summary of results
for each group is given, and the estimated effect size and its
precision (for example, 95% CI)
20 51 35 to 68 0.86 0.73 to 0.99
18 Ancillary
analyses
Clear statement of whether subgroup/adjusted analyses were
prespecified or exploratory
20 51 35 to 68 0.66 0.31 to 0.97
19 Harms Description of all important adverse events in each group 16 41 25 to 57 0.73 0.62 to 0.96
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journal, collaboration research of different countries,
region in which trials were conducted, funding source,
choice of comparator interventions) were extracted (by
Chun Zhang). Relevant studies were then photocopied
with the author’s names, date and institution excluded
for following rating by two assessors (Baoying Chen and
Jian Liu). Two independent assessors (Baoying Chen and
Jian Liu) blinded to each other’s ratings, completed the
rating form independently. Cohen’s к-statistic was calcu-
lated to assess agreement between two assessors. Agree-
ment was judged as poor if к≤ 0.20; fair if 0.20 lower than
к≤ 0.40; moderate if 0.40 lower than к≤ 0.60; substantial
if 0.60 lower than к≤ 0.80; good if к higher than 0.80; and
perfect if к = 1 [20]. Discrepancies were reviewed in detail
and subsequently settled by consensus.
Data analysis
The characteristics of the publications, scores of overall
reporting quality and five methodological items were
then described by descriptive analysis. To identify factors
associated with the overall quality of publications, we
used this overall score as the outcome variable and the
characteristics of the publications as independent variables
which was modeled using linear regression. Only variables
that were significant at P≤ 0.10 in the univariate modelswere used in a multivariable regression model for selecting
significant variables. Variables significant at the 5% level
in the final multivariable model were considered as sig-
nificant predictors. To analyze the relationship between
the score of overall reporting quality and year of publi-
cations, scatter plot and Pearson correlation analysis
were performed.
To identify factors associated with methodological
quality, we used this methodological score as the outcome
variable in the regression analyses. As the outcome vari-
able can be considered as a count, we relied on a Poisson
regression model and adjusted the variance empirically.
Descriptive statistical analysis, linear regression analysis,
scatter plot and Pearson correlation were performed using
SPSS version 20.0 (SPSS, Chicago, IL, USA). Analysis
of Poisson regression model and Cohen’s к-statistics
were performed using the SAS software, version 9.1
(SAS Institute, Inc, Cary, NC, USA). Database of RCTs
in MET for PCOS are provided in Additional file 1.
Results
The RCTs selection process is outlined in Figure 1. The
researchers applied the search method to find 225 reports
related to the topic, among which 35 reports of duplicates,
29 reports of non-MET therapy or PCOS, 23 reports of
animal experiments, reviews and comments are excluded.
Table 2 Reporting quality of key methodologic items (n = 39)
Item Criteria Description Number of
positive trials
% 95% CI Cohen’s к
coefficient
95% CI
8 Randomization Description of the method used to generate the
random sequence
26 67 51 to 82 0.83 0.72 to 0.98
9 and 10 Allocation concealment
and implementation
Description of the method used to implement the
random allocation sequence assuring the concealment
until interventions are assigned
19 49 31 to 64 0.71 0.55 to 0.94
11 Blinding Whether or not participants, those administering the
interventions, or those assessing the outcomes were
blinded to group assignment
20 51 27 to 55 0.72 0.48 to 0.95
15 Baseline data An outline of baseline demographic and clinical
characteristics of each group
38 97 92 to 100 0.65 0.49 to 0.97
16 Intention-to-treat analysis Number of participants in each group included in each
analysis and whether it was done by ‘intention-to-treat’
17 44 27 to 60 0.92 0.80 to 0.99
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further evaluation. Then researchers viewed the full text
of all potentially eligible reports were obtained and
picked out 16 case reports, 34 case series reports and 32
non-randomized controlled reports. Then, 56 RCTs pre-
liminarily were adopted. After carefully reselecting, we
pick out nine duplicated published reports and eight re-
ports not comparing MET and the other treatment. AFigure 1 Flowchart of the article selection process.total of 39 relevant RCTs were included in the final
analysis.
Characteristics of included trials
The characteristics of RCTs included in the final analysis
are described in Table 3. Counting the number of articles,
frequency, which refers to RCTs of MET for PCOS, was
found to be increasing over time: from 7 (17.9%) in 1996
Table 3 Characteristics of included randomized controlled
trials (RCTs) in metformin (MET) for polycystic ovary
syndrome (PCOS)
Features of included RCTs Number of
studies (n = 39)
%
Year of publication
1996 to 2001 7 17.9
2002 to 2007 12 30.8




Regions in which RCTs were conducted
North America 6 15.4
Europe 16 41.0
Others 17 43.6
Sources of trial funding
Yes 19 48.7
No 20 51.3
Collaboration of different countries
Yes 8 20.5
No 31 79.5
Choice of comparator interventions
Placebo 16 41.0
Sole intervention 11 28.2
MET plus other therapies 3 7.7
Some of above combinations 9 23.1
Journals with most frequently published
The Journal of Clinical Endocrinology &
Metabolism
9 23.1
Fertility and Sterility 7 17.9
Human Reproduction 6 15.4
The New England Journal of Medicine 3 7.7
Eleven other journalsa 14 35.9
Impact factors of included journalb
0.00 to 2.99 10 25.6
3.00 to 5.99 24 61.5
6.00- 4 10.3
Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; MET,
metformin; PCOS, polycystic ovary syndrome; RCT, randomized controlled trial.
aEach journal published fewer than three RCTs.
bOne journal (Acta Med Indones) did not have an impact factor.
Table 4 Multivariable linear regression analysis for
factors associated with better overall score from the
CONSORT statement (n = 39)
Variables β^ SE t s 95% CI
Constant 5.52 0.81 6.80 < 0.001 3.87 to 7.17
Funding source 1.71 0.75 2.27 0.030 0.18 to 3.24
Year of publication 3.51 0.83 4.22 < 0.001 1.82 to 5.19
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percentages of RCTs from North America and Europe
were 15.4% and 41.0%. More than half of included trials
neither got funding nor collaborated with researchers
from different countries. Sixteen RCTs (41.0%) chose
placebo as the comparator intervention. The RCTs were
published predominantly in three journals, namely TheJournal of Clinical Endocrinology & Metabolism (23.1%),
Fertility and Sterility (17.9%) and Human Reproduction
(15.4%).
Quality of reporting
Rating of overall reporting quality
The ratings of overall quality of reporting are listed in
Table 1. When the 39 RCTs were considered, the median
overall quality score was 9, with a minimum of 2 and a
maximum of 13. Good or general reporting existed in 11
items with positive rate of more than or equal to 50%,
while items of ‘sample size’ and ‘harms’ presented less
good reporting with positive rates of less than 50%.
Inter-rater agreements are reported for each item in
Tables 1 and 2. A substantial, good, or perfect agree-
ment was observed for 17 of 18 items. The inter-rater
agreement was considered as moderate for item 14 (28
February 2013).
Rating of Key Methodological Items
Randomization, allocation concealment and implemen-
tation, blinding, baseline characteristics and ITT analysis
were reported in 26 (67%), 19 (49%), 20 (51%), 38 (97%)
and 17 (44%) of the 39 RCTs, respectively (Table 2).
The median score of key methodological items was 4
with a minimum of 0 and a maximum of 5. Among the
39 studies, 1 (3%) did not report any of the five key
methodological items (Table 2).
Exploratory analysis: factors associated with better
reporting quality
In univariate analyses, year of publication and funding
source were associated with an increased overall score.
After adjustment, the multivariable linear regression
model suggested that these two factors remained signifi-
cant predictors of overall quality. Moreover, the mean
overall score increased by about 1.71 for manuscripts
with funding source (95% CI, 0.18 to 3.24; P < 0.05), while
it increased by about 3.51 for manuscripts published in
one year increment (95% CI, 1.82 to 5.19; P < 0.001)
(Table 4).
With regard to the methodological score, using uni-
variate Poisson regression, no variable was included in
the model.
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From Table 4, we saw the factor of year of publication is
a powerful predictor for overall reporting quality with its
coefficient 3.51. We want to know how the trend of
overall reporting quality in RCTs of MET for PCOS will
be with year increasing. There was a relatively close,
significant linear correlation (r = 0.589, P < 0.001) be-
tween the score of overall reporting quality and year of
publications (Figure 2).
Discussion
This study demonstrated that the quality of reporting in
RCTs on MET for PCOS was suboptimal especially in key
methodological items. This indicated that RCTs on MET
for PCOS syndrome needed improvement to meet the
level of ‘reporting quality’ required by the CONSORT
statement. It is important to follow the guidelines of the
CONSORT statement for RCTs on MET for PCOS for
two reasons. First, inconsistent findings of reviews [12,13]
or controversies [14-17] still existed in the effect of MET
on reproductive function in PCOS patients. Transparency
and accuracy of RCT reports will benefit the evidence-
based information extracting, assessing the validity of the
results and medical decision making. Second, standardized
report format allowed the reader to obtain more informa-
tion in a short time. Detailed and transparent reporting
made it easy to replicate the study and avoid the waste of
medical resources.Figure 2 Correlation between the score of overall reporting quality aWe identified five areas where information was insuffi-
cient or inadequate in most studies. These areas are sam-
ple size, harms, allocation concealment, blinding and ITT
analysis. Most importantly, the reporting quality of key
methodological items was poor. Our results are in agree-
ment with similar studies assessing the reporting quality
of RCTs published in other medical journals [27-29]. All
of them showed a suboptimal reporting quality, with key
methodologies being usually the most poorly reported
items. Allocation concealment, blinding, and ITT analysis
are critical in avoiding selection, performance/detection,
and attrition bias, respectively. An overestimation of
treatment effects has been demonstrated in trials with
inadequate key methodological design comparison with
trials that adequately reported these methodological
items [19].
Understanding the importance of transparency in re-
porting clinical trials, an international team, including
epidemiologists, statisticians and journal editors, devel-
oped the Consolidated Standards for Reporting Trials
(CONSORT) statement in 1996 [30]. The CONSORT
statement is an evidence-based set of recommendations
for reporting two-arm, parallel-group RCTs, including a
minimum set of items to be reported pertaining to the
rationale, design, analysis, and interpretation of the trial
(that is the CONSORT checklist) and a diagram describing
flow of participants through a trial (that is a flow dia-
gram). It is intended to facilitate the complete andnd year of publications.
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critical appraisal and interpretation. The effectiveness of
CONSORT in improving the reporting quality of RCTs
has been widely evaluated. A 2008 systematic evaluation
investigated whether there had been an improvement in
quality of reporting for RCTs since the publication of
CONSORT statements [31]. The results of this study sug-
gest that general standards of reporting for acupuncture
trials have significantly improved since the introduction
of the CONSORT statement in 1996 [31]. However, the
magnitude of improvement varied considerably among
included studies. A possible explanation for this vari-
ability is the lack of consistency in enforcing the use of
the CONSORT checklist among CONSORT adopter
journals. Cobo et al. [32] developed a RCT to investigate
the effect of an additional review based on reporting
guidelines such as CONSORT on quality of manuscripts.
They found that it is difficult for authors in adhering to
high methodological standards at the latest research
phases; to boost paper quality and impact, authors should
be aware of future requirements of reporting guidelines at
the very beginning of their study [32].
Interestingly, we find the overall reporting quality
of RCTs in MET for PCOS is improving with the
year increasing, which indicates that more and more
researchers and editors are realizing the importance
of reporting in RCTs due to the widely adoption and
promotion of CONSORT. The effect of CONSORT in
reporting RCTs of MET for PCOS still needs evaluation. A
future evaluation (for example, before and after study,
RCT) of the reporting quality after CONSORT endorse-
ment would be useful in assessing the effectiveness of this
measure. Meanwhile, our finding that the overall reporting
quality based on the CONSORT statement was correlated
with funding source, also suggested clinical trials with
funding have more capacity to provide assurance for the
better quality of study design and reporting of RCTs.
There are some limitations to our study. First, we
didn’t directly measure RCT methodological quality, be-
cause we did not verify the information from the authors
or their protocols. As important methodological criteria
may be omitted in published reports although adequately
carried out, the quality of reporting should be taken only
as an imperfect surrogate of true methodological quality.
Nevertheless published reports are the major source for
clinicians to judge the validity of the results, making the
quality of the report essential [20]. Second, to evaluate
the quality of reporting in RCTs quantitatively, according
to some rating methods published in previous studies
[20-23], we extracted major items, not all items, from the
CONSORT 2010 statement. Despite these limitations, we
think our results have good internal validity. In our survey,
the selection and abstraction processes were independ-
ently performed by two qualified assessors. Disagreementswere uncommon, and they occurred often due to lack of
transparency or contradictory information in the reports.
Conclusions
Our findings show that the reporting quality of RCTs in
MET for PCOS is suboptimal especially in key methodo-
logical items. Regarding the crucial methodological issues
of blinding, allocation concealment, and analysis by ITT,
our results stress the need for researchers involved in
RCTs of MET for PCOS to improve the methodological
quality of their research through a strengthened inter-
national collaboration. Reporting of RCTs on MET for
PCOS should meet and keep up with the standards of the
CONSORT statement.
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